IONIS PHARMACEUTICALS INCIONS
| Dec 31,
2010 | Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Revenue from the sale of medicines commercially as well as licensing and royalty revenues from other medicines, including SPINRAZA.. | - | - | - | - | - | - | - | - | 255 | 352 | 365 | 342 | 303 | 309 | 293 |
|---|
| Royalty revenues from the sale of SPINRAZA (nusinersen). | - | - | - | - | - | - | - | - | - | - | 287 | 268 | 242 | 240 | 216 |
|---|
| Royalty revenues from the sale of WAINUA (eplontersen). | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20 |
|---|
| Revenue from the sale of other medicines commercially as well as licensing and royalty revenue from other medicines, including TEGSEDI and WAYLIVRA. | - | - | - | - | - | - | - | - | - | - | - | - | - | 68 | 57 |
|---|
| Revenue from research and development services. | - | - | - | - | - | - | - | - | - | - | - | - | 284 | 479 | 412 |
|---|
| Revenue from research and development services performed under a collaborative agreement. | - | - | - | - | - | - | - | - | - | - | - | - | 207 | 353 | 333 |
|---|
| Joint development revenue for WAINUA (eplontersen). | - | - | - | - | - | - | - | - | - | - | - | - | - | 126 | 79 |
|---|
| Revenue | - | - | - | - | - | - | - | - | 600 | 1,123 | 729 | 810 | 587 | 788 | 705 |
|---|
| Cost of sales | - | - | - | - | - | - | - | - | 2 | 4 | 12 | 11 | 14 | 9 | 11 |
|---|
| The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense. | - | - | - | - | - | 322 | 344 | 375 | 415 | 466 | 535 | 643 | 833 | 900 | 902 |
|---|
| Selling, general and administrative | - | - | - | - | - | - | - | 108 | 245 | 287 | 354 | 186 | 150 | 233 | 267 |
|---|
| Total operating expenses | - | - | - | - | - | - | - | - | - | 757 | 901 | 841 | 998 | 1,141 | 1,180 |
|---|
| Loss from operations | -48 | -71 | -69 | -52 | -48 | -76 | -46 | 25 | -61 | 366 | -172 | -30 | -410 | -354 | -475 |
|---|
| Investment income | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 8 | 30 | 52 | 31 | 10 | 25 | 89 | 107 |
|---|
| Interest expense | 13 | 17 | 21 | 19 | 22 | 37 | 39 | 45 | 45 | 49 | 45 | 9 | 8 | 13 | 17 |
|---|
| Amount of interest expense using the effective interest rate method and amortization of issuance costs related to the sale of future royalties. | - | - | - | - | - | - | - | - | - | - | - | - | - | 69 | 73 |
|---|
| Loss on investments | -1 | 4 | 1 | 2 | 1 | - | - | - | - | - | 17 | 10 | -7 | -2 | -3 |
|---|
| Gain (loss) on sale of real estate assets | - | - | - | - | - | - | - | - | - | - | - | - | 150 | -0 | -0 |
|---|
| Other income (expense) | - | - | - | - | - | - | - | - | -0 | -1 | -0 | -1 | -7 | 14 | 1 |
|---|
| Loss before income tax benefit (expense) | - | -85 | -75 | -67 | -54 | -88 | -84 | - | - | - | - | -29 | -258 | -334 | -460 |
|---|
| Total income tax expense (benefit) | 0 | 0 | - | - | -15 | 0 | 3 | -6 | -291 | 44 | 317 | -1 | 12 | 32 | -6 |
|---|
| Net loss | -61 | -85 | -65 | -61 | -39 | -88 | -87 | -6 | 274 | 303 | -451 | -29 | -270 | -366 | -454 |
|---|
| Basic net loss per share (in dollars per share) | -0.62 | -0.85 | - | - | - | - | - | 0.08 | 2.09 | 2.12 | -3.23 | -0.2 | -1.9 | -2.56 | -3.04 |
|---|
| Diluted net loss per share (in dollars per share) | -0.62 | -0.85 | - | - | - | - | - | 0.08 | 2.07 | 2.08 | -3.23 | -0.2 | -1.9 | -2.56 | -3.04 |
|---|